Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2026-05-01 16:32:22 ET · period of report 2026-05-01 · accession 0001532218-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-05-01 16:32 | 2026-05-01 | KNSA | Patel Sanj K | COB, CEO, Dir | M - OptEx | $30.93 | +48.6K | 48.6K | New | +$1.50M |
| DT | 2026-05-01 16:32 | 2026-05-01 | KNSA | Patel Sanj K | COB, CEO, Dir | S - Sale+OE | $54.02 | -48.6K | 0 | -100% | -$2.62M |
| DT | 2026-05-01 16:32 | 2026-05-01 | KNSA | Patel Sanj K | COB, CEO, Dir | M - OptEx | $0.00 | -48.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2026-05-01 | M | A | 48,565 | $30.93 | 48,565 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. |
| 2 | Common | Class A Ordinary Share | 2026-05-01 | S | D | 48,565 | $54.02 | 0 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $54.00 and $54.155. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 3 | Derivative | Share Option | 2026-05-01 | M | D | 48,565 | $0.00 | 0 | D | $30.93 · — to 2028-09-19 | 48,565 Class A Ordinary Share | (F1) This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on October 31, 2025. (F3) The option is fully vested and exercisable. |